AcuityMD announced that it secured $80 million in a Series C funding round to support its AI-powered platform.
Boston-based AcuityMD develops a platform that translates large volumes of healthcare data into intuitive workflows and recommendations. These workflows and recommendations align with the medtech industry’s commercial process. Data translated includes physician procedural volumes, product preferences, sites of care affiliations, peer networks and referral patterns.
Related: ScreenPoint Medical raises $16M with continued investment from Siemens Healthineers
AcuityMD’s platform utilizes AI capabilities to deliver commercial insights required by medtech companies. It aggregates claims databases, FDA filings, government records and market signals to map physicians, facilities, networks, procedures, reimbursement dynamics and the relationships between them.
The Series C adds to a $45 million Series B round and a $31 million Series A. It brings the company’s funding to more than $160 million to date. The company touts a valuation of $955 million. Existing investor StepStone Group led the financing with additional participation from Benchmark, Redpoint Ventures, ICONIQ and Atreides Management.
AcuityMD plans to use its new capital to accelerate agentic AI capabilities, deepen its medtech ontology to power its data model and expand its platform beyond commercial to move into the full product lifecycle.
Mike Monovoukas, CEO and co-founder of AcuityMD, said:
“AI will transform MedTech, but only with the right context, deeply embedded in the workflows where decisions are made. AcuityMD is that context layer, serving the rep in the field, the commercial leader planning territories, and the teams launching the next generation of innovation. I’m grateful to the hundreds of customers who have helped shape our platform. This funding accelerates our shared mission of accelerating adoption of cutting-edge medical technologies.”
Hunter Somerville, partner at StepStone Group, said:
“AcuityMD is scaling rapidly while continuing to invest thoughtfully in its people and platform. The depth of the company’s data provides a meaningful advantage, and as AI capabilities continue to advance, that foundation becomes more valuable. We also see significant opportunities for AcuityMD to benefit the broader MedTech organization beyond commercial, reinforcing our decision to deepen our commitment.”
Mark Edwards, senior director of sales operations at Kuros Biosciences, said:
“AcuityAI has given our commercial team sharper answers, faster. Insights that used to take hours are now surfaced right when our reps need them, leading to richer conversations and opportunities we might otherwise have missed. One of our sales leaders asked AcuityAI for intel on a new national contract with a large health system, and quickly had a full business plan: where to go, which surgeons to prioritize, and more context than he could get spending hours on Google.”
